Literature DB >> 16187776

Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment.

Nienke H Tenneij1, Harold J G M van Megen, Damiaan A J P Denys, Herman G M Westenberg.   

Abstract

OBJECTIVE: In many patients with obsessive-compulsive disorder (OCD), residual symptoms persist despite a clinically meaningful response. The objective of this study was to examine whether addition of behavior therapy would augment treatment outcome in these patients.
METHOD: Ninety-six patients with DSM-IV OCD who had responded to 3 months of drug treatment were randomly assigned to either receive addition of behavior therapy or continue on drug treatment alone for 6 months. Patients who continued on drug treatment alone eventually received addition of behavior therapy for 6 months. Data were gathered from October 1998 to June 2002.
RESULTS: OCD patients who received addition of behavior therapy showed a greater improvement in obsessive-compulsive symptoms (Yale-Brown Obsessive Compulsive Scale [Y-BOCS] score change = -3.9 in the completers sample) than those who continued on drug treatment alone (Y-BOCS score change = +3.9 for completers). Significantly more patients who received addition of behavior therapy were in remission compared with those who continued on drug treatment alone (p < .0001 for completers). Patients who received behavior therapy after 6 months of drug treatment alone showed a nonsignificant decline in obsessive-compulsive symptoms (Y-BOCS score change = -2.7 for completers); however, the remission rate found in this group was comparable to the remission rate found in the group of patients receiving addition of behavior therapy directly after responding to drug treatment.
CONCLUSION: The results indicate that addition of behavior therapy is beneficial for patients who have responded to drug treatment. The data also suggest that the effect is greater when behavior therapy is added immediately after attainment of the drug response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187776     DOI: 10.4088/jcp.v66n0913

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

1.  Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.

Authors:  Martin E Franklin; Jeffrey Sapyta; Jennifer B Freeman; Muniya Khanna; Scott Compton; Daniel Almirall; Phoebe Moore; Molly Choate-Summers; Abbe Garcia; Aubrey L Edson; Edna B Foa; John S March
Journal:  JAMA       Date:  2011-09-21       Impact factor: 56.272

Review 2.  Obsessive compulsive disorder.

Authors:  G Mustafa Soomro
Journal:  BMJ Clin Evid       Date:  2012-01-18

3.  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

4.  An update on the efficacy of psychological therapies in the treatment of obsessive-compulsive disorder in adults.

Authors:  Kathryn Ponniah; Iliana Magiati; Steven D Hollon
Journal:  J Obsessive Compuls Relat Disord       Date:  2013-04-01       Impact factor: 1.677

5.  Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.

Authors:  Edna B Foa; Helen Blair Simpson; David Rosenfield; Michael R Liebowitz; Shawn P Cahill; Jonathan D Huppert; James Bender; Carmen P McLean; Michael J Maher; Raphael Campeas; Chang-Gyu Hahn; Patricia Imms; Anthony Pinto; Mark B Powers; Carolyn I Rodriguez; Page E Van Meter; Donna Vermes; Monnica T Williams
Journal:  J Clin Psychiatry       Date:  2015-04       Impact factor: 4.384

6.  More than Medication-Achieving Goals through Psychotherapy in Patients with Obsessive Compulsive Disorder.

Authors:  J Scott Wilson; Brenda Jb Roman
Journal:  Psychiatry (Edgmont)       Date:  2007-01

7.  Statistical choices can affect inferences about treatment efficacy: a case study from obsessive-compulsive disorder research.

Authors:  Helen Blair Simpson; Eva Petkova; Jianfeng Cheng; Jonathan Huppert; Edna Foa; Michael R Liebowitz
Journal:  J Psychiatr Res       Date:  2007-09-24       Impact factor: 4.791

8.  Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis.

Authors:  Pim Cuijpers; Marit Sijbrandij; Sander L Koole; Gerhard Andersson; Aartjan T Beekman; Charles F Reynolds
Journal:  World Psychiatry       Date:  2014-02       Impact factor: 49.548

9.  A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Deborah Roth Ledley; Jonathan D Huppert; Shawn Cahill; Donna Vermes; Andrew B Schmidt; Elizabeth Hembree; Martin Franklin; Raphael Campeas; Chang-Gyu Hahn; Eva Petkova
Journal:  Am J Psychiatry       Date:  2008-03-03       Impact factor: 18.112

10.  Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder.

Authors:  Edna B Foa; Helen Blair Simpson; Michael R Liebowitz; Mark B Powers; David Rosenfield; Shawn P Cahill; Raphael Campeas; Martin Franklin; Chang-Gyu Hahn; Elizabeth A Hembree; Jonathan D Huppert; Andrew B Schmidt; Donna Vermes; Monnica T Williams
Journal:  J Clin Psychiatry       Date:  2013-05       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.